Materialise Partners with University of Michigan and Tissue Regeneration Services for Clinical Trials of 3D Printed Tracheal Splint
New parents, while overjoyed at the life they have created, also tend to be filled with fear: What if I’m a terrible parent? What if I do something wrong? And, perhaps the most pervasive fear: What if there’s something wrong with my baby? While medical resources, at least in developed countries, are better than they’ve ever been, there are still a lot of conditions that can affect infants and keep their parents up all night with worry. One of these conditions is tracheobronchomalacia (TBM), a life-threatening, congenital condition that affects one in 2,200 babies. TBM causes the airway to periodically collapse, dangerously affecting breathing.
While the thought of TBM might make parents break out into a cold sweat, there is hope. Dr. Scott Hollister, a biomedical engineering professor at the University of Michigan, and Dr. Glenn Green, an otolaryngologist at C.S. Mott Children’s Hospital, invented a tracheal splint using 3D printing in 2012. The splint, implanted in the trachea of a baby with TBM, keeps the airway open until it can grow into a healthy state and stay open on its own. This process takes about three years, at which point the splint will dissolve and be absorbed by the body. We’ve already seen examples of the lifesaving potential of this device, but it’s been continually under development and hasn’t been widely available yet.
That should change thanks to two new partnerships: one between Materialise and the University of Michigan, the other between Materialise and Tissue Regeneration Systems (TRS). The University of Michigan has signed a licensing agreement with Materialise, whose Mimics Innovation Suite was used to design the tracheal splint. The agreement will allow for the commercialization of the device, which will begin with a clinical trial involving 30 patients at Mott Children’s Hospital sometime next year.
“This agreement is a critical step in our goal to make this treatment readily available for other children who suffer from this debilitating condition,” said Dr. Green. “We have continued to evolve and automate the design process for the splints, allowing us to achieve in two days what used to take us up to five days to accomplish. I feel incredibly privileged to be building products that surgeons can use to save lives.”
The bioresorbable splints will be manufactured by Plymouth, Michigan startup Tissue Regeneration Systems, which received its first commercial product clearance from the FDA in 2013 after several years of product development.
TRS has also worked with the University of Michigan in the past; in 2007, the company licensed a bioresorbable technology platform used to design the splint from the university. The splints are custom-designed based on patients’ CT scans and manufactured with a biodegradable biopolymer called polycaprolactone.
“The collaboration between TRS and Materialise will provide production capacity for the tracheal splint, which will allow the splint to be available to a larger number of infants who are affected with TBM,” said Bryan Crutchfield, Managing Director, Materialise USA.
Regarding the partnership with U of M, he added: “Here at Materialise, we strongly believe in the transformative power of great collaborations, such as the one we have enjoyed these past two years with Dr. Green, Dr. Hollister, and all others who have contributed to this live-saving application of 3D printing. This collaboration is proof that when the right skill sets and technologies are combined, solutions can be found for problems once thought impossible.”
Materialise, which serves a wide array of industries including automotive, aerospace, and consumer products, recently announced that they will be expanding their production of medical models and focusing more on the healthcare field.
“It was the possibility to realize 3D-printing enabled medical applications that, in part, motivated me to start Materialise 25 years ago,” said Materialise founder and CEO Fried Vancraen. “Today, we are proud to offer an entire range of software and services that can help universities, research centers, medical device companies, and hospitals develop solutions that result in a better and healthier world, such as the treatment developed for children diagnosed with TBM.”
Discuss this story in the Materialise 3D Printed Tracheal forum on 3DPB.com.
You May Also Like
QuesTek Innovations Wins US Air Force-America Makes 3D Printing Challenge
QuesTek Innovations has won the Macroscale Structure-to-Properties Predictions portion of an intensive four-part AFRL AM Modeling Challenge Series sponsored by the Air Force Research Laboratory (AFRL) and America Makes. Founded in 2012,...
Additive Manufacturing Strategies 2021 Moves Online, Adds Extra 3D Printing Vertical
Additive Manufacturing Strategies (AMS), the annual summit co-hosted by 3DPrint.com and SmarTech Analysis, is a conference focused on business intelligence for the additive manufacturing industry. The first year, AMS was...
ExOne’s 3D Sand Printing Network Expands Accessibility in North America
ExOne is a pioneer in sand 3D printing, licensed since 1996 to continue developing industrial inkjet 3D printing originally created by engineers at Massachusetts Institute of Technology (MIT) for use...
Markforged Metal 3D Printing Replaces Obsolete Part for Legacy Race Car
Founded in 2013 by Greg Mark, Massachusetts-headquartered Markforged quickly became a powerful presence in the 3D printing industry, first with carbon fiber reinforced 3D printing and then developing a novel...
View our broad assortment of in house and third party products.